Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
11:31am, Wednesday, 05'th Nov 2025
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Hims & Hers: GLP-1 Partnership Could Unlock Value
07:02am, Wednesday, 05'th Nov 2025
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho
Market Today: AMD beats, U.S. Steel plans, GLP-1 deal, Bitcoin drops
05:34pm, Tuesday, 04'th Nov 2025
Guru Stock PicksMatthews Japan Fund has made the following transactions:Reduce in TSE:2802 by 44.5%Sold out in TSE:3774Add in TSE:6503 by 77.82%New position in
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
12:00pm, Tuesday, 04'th Nov 2025
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (T
Eli Lilly Raises Outlook on Soaring GLP-1 Demand
07:20am, Thursday, 30'th Oct 2025
Eli Lilly reported higher third-quarter profit and raised its full-year outlook on the back of surging demand for its GLP-1 weight-loss drugs.
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
02:02pm, Wednesday, 29'th Oct 2025
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, wit
Global Partners Declares Third-Quarter 2025 Cash Distribution of $0.7550 on Common Units
08:30am, Tuesday, 28'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
08:00am, Monday, 27'th Oct 2025
SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines compa
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a regenerative medicine innovator focused on s
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
12:36am, Monday, 27'th Oct 2025
China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in N
Global Partners LP to Host Third-Quarter 2025 Financial Results Conference Call on November 7, 2025
08:30am, Friday, 24'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its third-quarter 2025 financial results before th
West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand
12:16pm, Thursday, 23'rd Oct 2025
West Pharmaceutical Services, Inc. (NYSE:WST) shares surged Thursday after the injectable pharmaceutical packaging and delivery systems company's third-quarter 2025 earnings surpassed analyst estimate
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
04:05pm, Tuesday, 21'st Oct 2025
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participan
Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill
03:27pm, Tuesday, 21'st Oct 2025
A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives Trump credit on drug prices.
